(Q46965067)

26 December 2017

title

Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. (English)

1 reference

26 December 2017

1 reference

15

Takao Koike

1 reference

26 December 2017

author name string

Hiroyuki Gatanaga

1

1 reference

26 December 2017

Tsunefusa Hayashida

2

1 reference

26 December 2017

Kiyoto Tsuchiya

3

1 reference

26 December 2017

Munehiro Yoshino

4

1 reference

26 December 2017

Takeshi Kuwahara

5

1 reference

26 December 2017

Hiroki Tsukada

6

1 reference

26 December 2017

Katsuya Fujimoto

7

1 reference

26 December 2017

Isao Sato

8

1 reference

26 December 2017

Mikio Ueda

9

1 reference

26 December 2017

Masahide Horiba

10

1 reference

26 December 2017

Motohiro Hamaguchi

11

1 reference

26 December 2017

Masahiro Yamamoto

12

1 reference

26 December 2017

Noboru Takata

13

1 reference

26 December 2017

Akiro Kimura

14

1 reference

26 December 2017

Fumitake Gejyo

16

1 reference

26 December 2017

Shuzo Matsushita

17

1 reference

26 December 2017

Takuma Shirasaka

18

1 reference

26 December 2017

Satoshi Kimura

19

1 reference

26 December 2017

Shinichi Oka

20

1 reference

26 December 2017

language of work or name

English

0 references

publication date

24 September 2007

1 reference

26 December 2017

Clinical Infectious Diseases

published in

1 reference

26 December 2017

volume

45

1 reference

26 December 2017

issue

9

1 reference

26 December 2017

page(s)

1230-1237

1 reference

26 December 2017

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

cites work

1 reference

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.

21 January 2018

1 reference

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

21 January 2018

1 reference

Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects

21 January 2018

1 reference

Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study

21 January 2018

1 reference

Three novel single nucleotide polymorphisms (SNPs) of the CYP2B6 gene in Japanese individuals.

21 January 2018

1 reference

Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz

21 January 2018

1 reference

Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes

21 January 2018

1 reference

Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression

21 January 2018

1 reference

Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles

21 January 2018

1 reference

A natural CYP2B6 TATA box polymorphism (-82T--> C) leading to enhanced transcription and relocation of the transcriptional start site.

21 January 2018

1 reference

Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.

21 January 2018

1 reference

Efavirenz intoxication due to slow hepatic metabolism

21 January 2018

1 reference

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/522175

1 reference

26 December 2017

PubMed ID

17918089

1 reference

26 December 2017